Associations between CDH1 gene polymorphisms and the risk of gastric cancer: A meta-analysis based on 44 studies

Abstract

Background: Numerous studies have investigated the association between CDH1 polymorphisms and gastric cancer (GC) risk. However, the results have been inconsistent and controversial. To further determine whether CDH1 polymorphisms increase the risk of GC, we conducted a meta-analysis by pooling the data.

Methods: Relevant case-control studies were collected from PubMed, Embase, Web of Science and Cochrane databases up to January 7, 2024. Subsequently, odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the strength of correlations. A sensitivity analysis was performed to evaluate the robustness and reliability of these included studies.

Results: A total of 25 articles including 44 studies, were included in this meta-analysis, including 26 studies on rs16260, 6 studies on rs3743674, 7 studies on rs5030625, and 5 studies on rs1801552. The pooled results showed that rs16260 was remarkably associated with an increased GC risk of GC among Caucasians. Moreover, the rs5030625 variation dramatically enhanced GC predisposition in the Asian population. However, no evident correlations between CDH1 rs3743674 and rs1801552 polymorphisms and GC risk were observed.

Conclusions: Our findings suggested that CDH1 gene polymorphisms were significantly correlated with GC risk, especially in rs16260 and rs5030625 polymorphisms.

Figure 1.

Flow diagram of the eligible study selection process.

Figure 2.

Association between CDH1 rs16260 gene polymorphism and GC risk in all 5 models. (A) Allele model; (B) dominant model; (C) heterozygote model; (D) homozygote model; (E) recessive model. CDH1 = E-cadherin, GC = gastric cancer.

Figure 3.

Association between CDH1 rs3743674 gene polymorphism and GC risk in all 5 models. (A) allele model; (B) dominant model; (C) heterozygote model; (D) homozygote model; (E) recessive model. CDH1 = E-cadherin, GC = gastric cancer.

Figure 4.

Association between CDH1 rs5030625 gene polymorphism and GC risk in all 5 models. (A) allele model; (B) dominant model; (C) heterozygote model; (D) homozygote model; (E) recessive model. CDH1 = E-cadherin, GC = gastric cancer.

Figure 5.

Association between CDH1 rs1801552 gene polymorphism and GC risk in all 5 models. (A) allele model; (B) dominant model; (C) heterozygote model; (D) homozygote model; (E) recessive model. CDH1 = E-cadherin, GC = gastric cancer.

Figure 6.

Sensitivity analysis through deletion of one study at a time to reflect the influence of the individual dataset to the pooled ORs in CDH1 gene polymorphisms under the dominant model. (A) the rs16260 polymorphism; (B) the rs3743674 polymorphism; (C) the rs5030625 polymorphism; (D) the rs1801552 polymorphism. CDH1 = E-cadherin, OR = odds ratio.

Figure 7.

Begg’s funnel plot and Egger’s linear regression plot for detecting the publication bias through the dominant model. (A) Begg’s test for rs16260 polymorphism; (B) Egger’s test for rs16260 polymorphism; (C) Begg’s test for rs3743674 polymorphism; (D) Egger’s test for rs3743674 polymorphism; (E) Begg’s test for rs5030625 polymorphism; (F) Egger’s test for rs5030625 polymorphism; (G) Begg’s test for rs1801552 polymorphism; (H) Egger’s test for rs1801552 polymorphism.